Menu Back toSession 4: Cross Industry Consortia Addressing RWE: Impact and Future Directions

Real-World Evidence Conference

Translating Insights into Real-World Value.


Session 4: Cross Industry Consortia Addressing RWE: Impact and Future Directions

Session Chair(s)

David  Martin, MD, MPH

David Martin, MD, MPH

  • Vice President, Clinical Safety and Risk Management
  • Moderna, United States
Sulabha  Ramchandran, PhD, MS

Sulabha Ramchandran, PhD, MS

  • Vice President and Head, US and Regions, Value Evidence and Outcomes
  • GlaxoSmithKline, United States
This session will bring together leaders from cross-industry consortia to discuss key strategic objectives for RWE. Speakers will address existing RWE initiative priorities, deliverables to date, key learnings, and the manner in which they are shaping future priorities. Participants will be exposed to resources for best practices, assess opportunities to engage, consider applications within biopharmaceutical development.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Gain awareness of the strategic goals and foci of cross-industry RWE initiatives
  • Identify key learnings and deliverables generated to date
  • Apply key resources for best practices and assess opportunities to engage

Speaker(s)

Rebecca  Lipsitz, PhD

PhRMA and Bio RWE Initiatives

Rebecca Lipsitz, PhD

  • Senior Director, TA Regulatory Intelligence and Portfolio Policy, Late R&I RA
  • AstraZeneca, United States
Cathy W Critchlow, PhD, MSc

Transcelerate RWE Workstreams

Cathy W Critchlow, PhD, MSc

  • Vice President, R&D Data Strategy
  • Amgen Inc., United States
William H. Crown, PhD, MA

Learnings from OPERAND

William H. Crown, PhD, MA

  • Distinguished Research Scientist, Heller School for Social Policy and Management
  • Brandeis University , United States
Morgan  Romine, MPA

Overview of Duke Margolis RWE Initiatives

Morgan Romine, MPA

  • Chief of Staff
  • Duke University, United States
Jeff  Allen, PhD

FOCR Oncology RWE Validation and Endpoints

Jeff Allen, PhD

  • President and Chief Executive Officer
  • Friends of Cancer Research, United States